AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 282 min read$LH

Labcorp Q3 Earnings Call Highlights

Labcorp reported Q3 revenue growth of 8.5% in biopharma services, with central lab services up 11.3%. Adjusted operating income rose to $159M. The company raised 2026 revenue and EPS guidance, citing strong organic performance. Labcorp also addressed PAMA-related reimbursement pressures expected in 2027 and announced several acquisitions.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 5:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 5:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Labcorp Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$LHBullishHigh
01

Why it matters

The guidance raise is the most material new information, likely moving the stock.

02

Market read

First report of a significant guidance increase for a large-cap healthcare provider.

03

What to watch

Potential regulatory headwinds from PAMA and integration risk of recent acquisitions could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Labcorp reported Q3 results, highlighted BLS revenue growth, and announced several acquisitions and specialty-test launches.

Company-level read

Ticker impact

$LHBullishHigh confidence
Context

Labcorp raised its 2026 revenue midpoint by $65M and adjusted EPS midpoint by $0.18, providing fresh guidance.

Expected impact

likely upward pressure as market prices in higher revenue and EPS expectations

Evidence & confidence

Guidance lift is a primary disclosure for a large cap; traders may buy on the news.

Market effects

Sector

Higher guidance may boost sentiment for the broader diagnostics and biotech services sector.

Regional

U.S. healthcare stocks could see modest gains.

Global

Limited to investors tracking U.S. lab services firms.

Counterpoint

What could challenge this read

Some investors may question the sustainability of growth given upcoming PAMA reimbursement pressure in 2027.

Key entities

  • company
    Labcorp

    Global life sciences and healthcare company (NYSE:LH).

Read at source← All news

StoryLabcorp posts Q3 2026 revenue and adjusted EPS growth and lifts full‑year guidance

Also covered by

5 outlets

Related articles

OCT 28
$LHHighAI 8/10

Labcorp (LH) Q3 2026 Earnings Call Transcript

LabCorp (LH) reported Q3 2026 revenue growth of 7% to $3.8B, EPS growth of 14.5% to $4.78, and raised 2026 guidance. The company expressed concerns over proposed PAMA fee schedule changes, which may reduce Medicare reimbursement rates. LabCorp highlighted growth in diagnostics and biopharma services, FDA approvals, and strategic acquisitions, including MLM Medical Labs and agreements with Myriad Genetics and Millennium Health.

finance.yahoo.com3 min
OCT 28
$LHMedAI 8/10

Labcorp Holdings Inc. Q3 2026 Earnings Call Summary

Labcorp reported 7% revenue growth in Q3 2026, driven by diagnostics and biopharma. Enterprise margin expanded by 60 basis points. The company raised full-year guidance despite $10M in foreign currency headwinds. Management expects a $125M impact from PAMA in 2027. Recent acquisitions and the Launchpad initiative aim to offset reimbursement pressures. Biopharma growth is expected to be high-single-digit, supported by an $8.9B backlog.

finance.yahoo.com3 min
OCT 28
$LHHighAI 9/10

Labcorp (LH) stock trades up, here is why

Labcorp (LH) shares rose 10.3% after reporting Q3 revenue of $3.81B, beating estimates, and raising its full-year 2026 outlook to 5.9-6.7% revenue growth and $18.30-$18.70 adjusted EPS. The company's stock has gained 45.4% year-to-date, reaching a 52-week high of $365.79.

stockstory.org2 min
OCT 28
$WENMed

Stocks making the biggest moves midday: Wendy's, Wingstop, F5, Enphase Energy, Labcorp & more

Wendy's rose 15% on a $1.4B privatization proposal from Trian Fund. Brinker International and Wingstop gained 15% after raising guidance and beating earnings. F5 dropped 19% on weak guidance and a downgrade. Labcorp and GE HealthCare advanced on raised guidance. Ultralife surged 145% on a $320M acquisition deal. Enphase Energy fell 16% on missed revenue. PPG Industries rose 6% on earnings beat and raised guidance. Robinhood fell 2% on missed profit. SK hynix advanced 11% on strong earnings.

cnbc.com3 min